Semaglutide Dosing and Administration Guidelines

Introduction to Semaglutide Titration

• The American Gastroenterological Association recommends a gradual dose titration protocol for semaglutide, starting at 0.25 mg subcutaneously once weekly for 4 weeks, then escalating by increments every 4 weeks to minimize gastrointestinal adverse effects while achieving therapeutic benefit 1, 2, 3

Standard Titration Schedule

• For weight management, the standard titration schedule is as follows:
• For type 2 diabetes, the initial dose is 0.25 mg once weekly for 4 weeks, then increased to 0.5 mg, and finally to 1 mg weekly as needed for glycemic control 3

Critical Implementation Points

• Gradual titration is essential to minimize gastrointestinal adverse effects, including nausea, vomiting, and diarrhea, which are dose-dependent and more frequent with rapid escalation 1, 2, 3, 4

Administration Technique

• Semaglutide should be injected subcutaneously once weekly at any time of day, independent of meals, and injection sites should be rotated within the abdomen, thigh, or upper arm 3, 5

Contraindications and Precautions

• Absolute contraindications include personal or family history of medullary thyroid cancer, multiple endocrine neoplasia syndrome type 2, pregnancy, and breastfeeding 1, 2, 5
• Semaglutide should be used with caution in patients with a history of pancreatitis, as current guidelines recommend caution if GLP-1 receptor agonists are needed in these patients 4

Long-Term Considerations

• Semaglutide should be considered lifelong therapy, as weight regain occurs after discontinuation, and cardiovascular benefits require ongoing treatment 3, 4, 5
• The cardiovascular benefits of semaglutide are substantial, with a reduced primary cardiovascular endpoint (death from cardiovascular causes, non-fatal MI, or non-fatal stroke) from 8.2% to 6.5% (p=0.001) in patients with pre-existing cardiovascular disease 4